Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $6.00 to $5.00. The current price Evelo Biosciences (EVLO) is trading at is $2.35, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/24/2022 | 112.77% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 112.77% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 1665.96% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 410.64% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 1517.02% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 1091.49% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 453.19% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 665.96% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 495.74% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1048.94% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 155.32% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 240.43% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 793.62% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 155.32% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 665.96% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 325.53% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 1176.6% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 1176.6% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 1134.04% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 963.83% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 1006.38% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 8 月 24 日 | 112.77% | 摩根士丹利 | 6 美元 → 5 美元 | 维护 | 重量相等 |
| 08/15/2022 | 112.77% | 查丹资本 | 12 美元 → 5 美元 | 维护 | 买 |
| 11/02/2021 | 1665.96% | JMP 证券 | 44 美元 → 41.5 美元 | 维护 | 市场表现跑赢大盘 |
| 11/01/2021 | 410.64% | 查丹资本 | → 12 美元 | 升级 | 中性 → 买入 |
| 06/23/2021 | 1517.02% | JMP 证券 | 36 美元 → 38 美元 | 维护 | 市场表现跑赢大盘 |
| 06/23/2021 | 1091.49% | 坎托·菲茨杰拉德 | → 28 美元 | 启动覆盖范围开启 | → 超重 |
| 05/03/2021 | 453.19% | 摩根士丹利 | 14 美元 → 13 美元 | 维护 | 重量相等 |
| 2021 年 12 月 4 日 | 665.96% | 杰富瑞集团 | 11 美元 → 18 美元 | 升级 | 持有 → 买入 |
| 01/19/2021 | 495.74% | 摩根士丹利 | 6 美元 → 14 美元 | 维护 | 重量相等 |
| 12/23/2020 | 1048.94% | JMP 证券 | → 27 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 11/11/2020 | 155.32% | 摩根士丹利 | 8 美元 → 6 美元 | 维护 | 重量相等 |
| 05/21/2020 | 240.43% | 摩根士丹利 | → 8 美元 | 降级 | 超重 → 重量相等 |
| 05/12/2020 | 793.62% | BMO Capital | 24 美元 → 21 美元 | 维护 | 跑赢大盘 |
| 05/12/2020 | 155.32% | 杰富瑞集团 | 18 美元 → 6 美元 | 降级 | 买入 → 持有 |
| 2019 年 4 月 30 日 | 665.96% | 杰富瑞集团 | → 18 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 1 月 29 日 | 325.53% | 查丹资本 | → 10 美元 | 启动覆盖范围开启 | → 中立 |
| 10/12/2018 | 1176.6% | 摩根士丹利 | 29 美元 → 30 美元 | 维护 | 超重 |
| 10/11/2018 | 1176.6% | 摩根士丹利 | 29 美元 → 30 美元 | 维护 | 超重 |
| 2018 年 4 月 6 日 | 1134.04% | 摩根士丹利 | → 29 美元 | 启动覆盖范围开启 | → 超重 |
| 2018 年 4 月 6 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2018 年 4 月 6 日 | 963.83% | JMP 证券 | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2018 年 4 月 6 日 | 1006.38% | BMO Capital | → 26 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
Evelo Biosciences Questions & Answers
Evelo Biosciences 问题与解答
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Morgan Stanley on August 24, 2022. The analyst firm set a price target for $5.00 expecting EVLO to rise to within 12 months (a possible 112.77% upside). 4 analyst firms have reported ratings in the last year.
摩根士丹利于2022年8月24日公布了Evelo Biosciences（纳斯达克股票代码：EVLO）的最新目标股价。该分析公司将目标股价定为5.00美元，预计EVLO将在12个月内升至12个月内（可能上涨112.77％）。去年有4家分析公司公布了评级。
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Morgan Stanley, and Evelo Biosciences maintained their equal-weight rating.
摩根士丹利对Evelo Biosciences（纳斯达克股票代码：EVLO）的最新分析师评级由摩根士丹利提供，而Evelo Biosciences维持同等权重评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on August 24, 2022 so you should expect the next rating to be made available sometime around August 24, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Evelo Biosciences的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Evelo Biosciences的最新评级是在2022年8月24日公布的，因此您应该预计下一个评级将在2023年8月24日左右公布。
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $6.00 to $5.00. The current price Evelo Biosciences (EVLO) is trading at is $2.35, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Evelo Biosciences（EVLO）评级维持不变，目标股价为6.00美元至5.00美元。Evelo Biosciences（EVLO）目前的交易价格为2.35美元，超出了分析师的预期区间。
